Protocol Ledger

NCT06724237 · Phase III · RECRUITING

Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

Interventional Phase III clinical trial protocol NCT06724237 sponsored by Eastern Cooperative Oncology Group in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-06-18 Enrollment: 294 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06724237
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)294 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06724237
Protocol FieldVerified Registry Value
NCT IdentifierNCT06724237
Consolidated Lead SponsorEastern Cooperative Oncology Group
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment294 participants (ESTIMATED)
Registered Start Date2025-06-18
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI